TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22967105

Group type: EXPERIMENTAL
Intervention: telbivudine 600 mg
Number of subjects: 232

Group type: COMPARATOR
Intervention: lamivudine 100 mg
Number of subjects: 232
Study: 19005477

Group type: EXPERIMENTAL
Intervention: Device-guided breathing (RESPeRATE), 15 min daily for 8 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (regular treatment)
Number of subjects: 66
Study: 17289891

Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg for the first dose, then 1.5 mg/kg monthly for a total of four cycles)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 11
Study: 16568918

Group type: EXPERIMENTAL
Intervention: P-ASA nerve block using CompuMed delivery system
Number of subjects: 21

Group type: COMPARATOR
Intervention: Traditional multiple supraperiosteal (TMS) injections
Number of subjects: 21
Study: 12512989

Group type: EXPERIMENTAL
Intervention: Crest SpinBrush (experimental power toothbrush)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Colgate Wave (control manual toothbrush)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Colgate Plus (control manual toothbrush)
Number of subjects: 72
Study: 10341999

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 26
Study: 7727269

Group type: EXPERIMENTAL
Intervention: Cooperative environment
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Competitive environment
Number of subjects: 179

Group type: COMPARATOR
Intervention: Individualistic environment
Number of subjects: 179
Study: 2250075

Group type: EXPERIMENTAL
Intervention: Topically applied fluorescein gel
Number of subjects: 10
Study: 7449597

Group type: EXPERIMENTAL
Intervention: Computer-planned menus for diabetic patients
Number of subjects: 0
Study: 31084423

Group type: EXPERIMENTAL
Intervention: Mobile-based prevention intervention
Number of subjects: 0
Study: 27325226

Group type: COMPARATOR
Intervention: AC group (anticoagulant group)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Warfarin group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Dabigatran group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Apixaban group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Rivaroxaban group
Number of subjects: 103

Group type: COMPARATOR
Intervention: NOACs (non-vitamin K antagonist oral anticoagulants)
Number of subjects: 103
Study: 26026705

Group type: EXPERIMENTAL
Intervention: 24 intranasal units (IU) oxytocin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 24145941

Group type: EXPERIMENTAL
Intervention: Evidence based medicine (EBM) workshop
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (other primary health care activities)
Number of subjects: 148
Study: 20865424

Group type: EXPERIMENTAL
Intervention: Overweight youth during rest and exercise
Number of subjects: 146

Group type: COMPARATOR
Intervention: Normal weight youth during rest and exercise
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Overweight youth at 5.6 and 8 kph
Number of subjects: 146
Study: 19364421

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural pain management program (10 sessions)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 95
Study: 17485550

Group type: EXPERIMENTAL
Intervention: Real‐time quantitative polymerase chain reaction analysis of antigen receptor gene rearrangements for detection of minimal residual disease (MRD)
Number of subjects: 284
Study: 14870716

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 16
Study: 11175930

Group type: EXPERIMENTAL
Intervention: Dry Powder Inhaler (DPI) - transparent Rotahaler
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metered Dose Inhaler (MDI) with spacer
Number of subjects: 30
Study: 9594376

Group type: EXPERIMENTAL
Intervention: Osteogenesis imperfecta patients with dentinogenesis imperfecta (DI)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Osteogenesis imperfecta patients with DI
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Osteogenesis imperfecta type I patients with DI
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Osteogenesis imperfecta type III and IV patients with DI
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Osteogenesis imperfecta patients without DI
Number of subjects: 88

Group type: COMPARATOR
Intervention: Osteogenesis imperfecta patients
Number of subjects: 88
Study: 7737789

Group type: EXPERIMENTAL
Intervention: Psychiatric consultation intervention
Number of subjects: 106
Study: 2691211

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 804914

Group type: EXPERIMENTAL
Intervention: Cromoglycic acid tablets
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30796109

Group type: EXPERIMENTAL
Intervention: Metformin therapy in pre-DM patients
Number of subjects: 258

Group type: COMPARATOR
Intervention: Normoglycemia (NG)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Pre-DM patients
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Pre-DM metformin patients
Number of subjects: 258
Study: 27511957

Group type: EXPERIMENTAL
Intervention: Exercise intervention using a novel exercise park
Number of subjects: 0
Study: 26332915

Group type: EXPERIMENTAL
Intervention: Immediate PBM therapy (2 min treatment using a 4 W laser beam, 171 J delivered)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Delayed PBM therapy (2 min treatment using a 4 W laser beam, 171 J delivered)
Number of subjects: 80
Study: 23943845

Group type: EXPERIMENTAL
Intervention: Training during and after undergraduate studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training after studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training during undergraduate studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2005 vs 2010
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 0
Study: 21724005

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Regional intravenous anesthesia with lidocaine
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Regional intravenous anesthesia with lidocaine and clonidine
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Axillary plexus block
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Overall incidence of CRPS after CTR
Number of subjects: 301
Study: 19465624

Group type: EXPERIMENTAL
Intervention: Paramedic practitioner (PP) scheme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual emergency care (control)
Number of subjects: 0
Study: 16476941

Group type: EXPERIMENTAL
Intervention: SIB-1508Y (10 mg daily)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 15459829

Group type: EXPERIMENTAL
Intervention: Moderate intensity resistance exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control trial
Number of subjects: 9
Study: 11908373

Group type: EXPERIMENTAL
Intervention: Battery-powered toothbrush (Colgate Actibrush)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electric toothbrush (Braun Oral‐B Plaque Remover)
Number of subjects: 0
Study: 9323924

Group type: EXPERIMENTAL
Intervention: Laparotomy via the Rutherford‐Morrison incision (Group A)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Laparotomy via right paramedian incision (Group B)
Number of subjects: 56
Study: 8295604

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine tartrate (DHE) 2 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Combination of DHE 2 mg and paracetamol 1000 mg
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 3815266

Group type: COMPARATOR
Intervention: CFP (Cytoxan, 5-fluorouracil, prednisone)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: CFPMV (Cytoxan, 5-fluorouracil, prednisone, methotrexate, vincristine)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: CA (Cytoxan, Adriamycin)
Number of subjects: 141
Study: 30975712

Group type: EXPERIMENTAL
Intervention: Usual care plus advance care planning (ACP)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Usual care plus ACP
Number of subjects: 205
Study: 30478122

Group type: EXPERIMENTAL
Intervention: Workplace smoking cessation group training programme with financial incentives
Number of subjects: 24
Study: 26632891

Group type: EXPERIMENTAL
Intervention: Self-locating Wolfram catheter
Number of subjects: 61

Group type: COMPARATOR
Intervention: Straight Tenckhoff catheter
Number of subjects: 61
Study: 24041381

Group type: EXPERIMENTAL
Intervention: Ultrasonic activation of the irrigant
Number of subjects: 84

Group type: COMPARATOR
Intervention: Syringe irrigation (control)
Number of subjects: 84
Study: 21286740

Group type: EXPERIMENTAL
Intervention: iTBS plus ET
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: iTBS alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation plus ET
Number of subjects: 30
Study: 18176825

Group type: EXPERIMENTAL
Intervention: Topical metronidazole (10 percent)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 17342880

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (calcium-phosphate)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Exercise (active group)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (nonactive group)
Number of subjects: 160
Study: 15174232

Group type: EXPERIMENTAL
Intervention: Interferon beta 1a (Avonex) treatment, 30 mcg once a week
Number of subjects: 126
Study: 10868001

Group type: EXPERIMENTAL
Intervention: Self-management of oral anticoagulation
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Conventional care by a general practitioner or specialist
Number of subjects: 2000
Study: 9360409

Group type: EXPERIMENTAL
Intervention: Orlistat (intestinal lipase inhibitor)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 1390306

Group type: EXPERIMENTAL
Intervention: Low-dose continuous heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 4077235

Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg/day) for 6 to 8 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 31393424

Group type: COMPARATOR
Intervention: Usual care (routine radiographs at 6 and 12 weeks)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Reduced imaging (no routine radiographs at 6 and 12 weeks)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Reduced imaging
Number of subjects: 326
Study: 29887423

Group type: EXPERIMENTAL
Intervention: Intra-coronary sodium nitrite
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 27179727

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 13887

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily
Number of subjects: 13887
Study: 24507164

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise (40%-60% of Heart Rate Reserve (HRR))
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 87
Study: 23126254

Group type: EXPERIMENTAL
Intervention: ISBT combined with interstitial hyperthermia (ISHT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: ISBT alone (control group)
Number of subjects: 76
Study: 20556412

Group type: EXPERIMENTAL
Intervention: Verbal Instruction (VI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Verbal Instruction plus Augmented Feedback (VI + FB)
Number of subjects: 12
Study: 17386184

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 0
Study: 15976952

Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Delayed cholecystectomy
Number of subjects: 1014
Study: 16946363

Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg/day
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg/day
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: paroxetine 20 mg/day
Number of subjects: 681

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 681
Study: 10322590

Group type: EXPERIMENTAL
Intervention: Application of a semirigid ankle brace (Aircast Air-Stirrup)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nonbraced condition
Number of subjects: 11
Study: 8647140

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg modified release formulation once daily)
Number of subjects: 244
Study: 1825323

Group type: EXPERIMENTAL
Intervention: etodolac 200 mg b.i.d.
Number of subjects: 48

Group type: COMPARATOR
Intervention: naproxen 500 mg b.i.d.
Number of subjects: 48
Study: 6836825

Group type: EXPERIMENTAL
Intervention: Single dose of gentamicin two hours preoperatively
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three schedules of gentamicin administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0
Study: 30316534

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 U vitamin D3 pearl weekly for 8 weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 30016983

Group type: EXPERIMENTAL
Intervention: Xiaozhen formula and basic treatment
Number of subjects: 266

Group type: COMPARATOR
Intervention: Basic treatment only
Number of subjects: 266
Study: 26341604

Group type: EXPERIMENTAL
Intervention: S-ICD after TV-ICD extraction for system-related infection
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: S-ICD after TV-ICD extraction for reasons other than system-related infection
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: S-ICD de novo implantations
Number of subjects: 866
Study: 25438272

Group type: EXPERIMENTAL
Intervention: Rocuronium (R group; n = 22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline (S group; n = 22)
Number of subjects: 44
Study: 22812577

Group type: EXPERIMENTAL
Intervention: High dairy intake (4 servings of reduced-fat dairy per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dairy intake (1 serving of reduced-fat dairy per day)
Number of subjects: 0
Study: 21375022

Group type: EXPERIMENTAL
Intervention: Routine plus mental-regulating acupoints treatment group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (TENS, acupuncture, TDP irradiation, pellet-pressure)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Treatment sessions
Number of subjects: 20
Study: 17634487

Group type: EXPERIMENTAL
Intervention: Long-term androgen-deprivation therapy (LTAD) plus radiotherapy (RT)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Short-term androgen-deprivation therapy (STAD) plus radiotherapy (RT)
Number of subjects: 612
Study: 16287386

Group type: EXPERIMENTAL
Intervention: Mid-therapy emotional arousal
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mid- and late treatment perceptual processing
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Emotional arousal and perceptual processing during mid-therapy
Number of subjects: 32
Study: 11929394

Group type: EXPERIMENTAL
Intervention: Prucalopride 1 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Prucalopride 1 mg and 2 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 10517273

Group type: EXPERIMENTAL
Intervention: Surface electromyogram (SEMG) technique (189 MUs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cross-correlation of MU discharge (498 MU pairs)
Number of subjects: 16
Study: 7545763

Group type: EXPERIMENTAL
Intervention: Daily recombinant human growth hormone (rhGH), 0.15 mg/kg IM
Number of subjects: 18

Group type: COMPARATOR
Intervention: Not receiving rhGH (Control group)
Number of subjects: 18
Study: 31394380

Group type: EXPERIMENTAL
Intervention: BIONEX (EMG-biofeedback guided exercises)
Number of subjects: 49

Group type: COMPARATOR
Intervention: NEX (same exercises without EMG-biofeedback)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: BIONEX
Number of subjects: 49

Group type: COMPARATOR
Intervention: NEX
Number of subjects: 49
Study: 28117049

Group type: EXPERIMENTAL
Intervention: Bitopertin 5 mg
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Bitopertin 10 mg (DayLyte)
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Bitopertin 10 mg (FlashLyte)
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Bitopertin 20 mg (FlashLyte)
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199
Study: 26690825

Group type: EXPERIMENTAL
Intervention: High visceral fat to subcutaneous fat ratio (VFA/SFA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low visceral fat to subcutaneous fat ratio (VFA/SFA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Prognostic score combining VFA/SFA, LDH, and liver metastasis
Number of subjects: 42
Study: 23668834

Group type: EXPERIMENTAL
Intervention: Educational intervention (distribution of educational materials, online course, three on-site workshops)
Number of subjects: 3018

Group type: COMPARATOR
Intervention: Control group (baseline information collected retrospectively)
Number of subjects: 3018
Study: 21413974

Group type: EXPERIMENTAL
Intervention: Low dose BoNT‐B (1500 MU)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Medium dose BoNT‐B (3000 MU)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High dose BoNT‐B (5000 MU)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no BoNT‐B)
Number of subjects: 27
Study: 18499270

Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (maintenance therapy)
Number of subjects: 21
Study: 15766814

Group type: EXPERIMENTAL
Intervention: Primary PCI in women
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Primary PCI in men
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Female gender as a predictor
Number of subjects: 763
Study: 12032514

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no growth hormone treatment)
Number of subjects: 36
Study: 10232715

Group type: COMPARATOR
Intervention: 75 mg lidocaine 5% intrathecally (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.15 mg x kg(‐1) meperidine (group B) co-administered with lidocaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.30 mg x kg(‐1) meperidine (group C) co-administered with lidocaine
Number of subjects: 40
Study: 8730115

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) plus prednisone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 24
Study: 1862156

Group type: EXPERIMENTAL
Intervention: epictor (EGF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: platelet derived growth factor (PDGF)
Number of subjects: 0
Study: 6676478

Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate 0.04 mg kg‐1 BW iv
Number of subjects: 10

Group type: COMPARATOR
Intervention: Naloxone 3 micrograms kg‐1 BW iv
Number of subjects: 10
Study: 28261848

Group type: EXPERIMENTAL
Intervention: Dapoxetine (30 mg) on demand (Group 1)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Moderate physical activities (Group 2)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Minimal physical activity (Group 3 - sham)
Number of subjects: 105
Study: 26408420

Group type: EXPERIMENTAL
Intervention: rTMS + DIMST
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rTMS + sham-DIMST
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sham-rTMS + DIMST
Number of subjects: 0

Group type: COMPARATOR
Intervention: sham-rTMS + sham-DIMST
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All active groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All peripheral parameters
Number of subjects: 0
Study: 23907370

Group type: EXPERIMENTAL
Intervention: RT plus cetuximab
Number of subjects: 141

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 141
Study: 22127555

Group type: EXPERIMENTAL
Intervention: Alprazolam administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20669630

Group type: EXPERIMENTAL
Intervention: Multidrug chemotherapy regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 18715415

Group type: EXPERIMENTAL
Intervention: Immediate oxytocin administration
Number of subjects: 412

Group type: COMPARATOR
Intervention: Oxytocin withheld for up to 8 hours (conservative group)
Number of subjects: 412
Study: 16060280

Group type: EXPERIMENTAL
Intervention: Interference currents
Number of subjects: 0
Study: 12202899

Group type: EXPERIMENTAL
Intervention: Doxorubicin and paclitaxel (AT combination)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracyl, doxorubicin and cyclophosphamid (FAC)
Number of subjects: 0
Study: 10980848

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 0
Study: 7726087

Group type: COMPARATOR
Intervention: Cumulative standard dose (0.1 mmol/kg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cumulative triple dose (0.3 mmol/kg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Delayed imaging after injection of standard contrast dose
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Delayed imaging after injection of higher contrast dose
Number of subjects: 45
Study: 2343736

Group type: EXPERIMENTAL
Intervention: Interpleural injection of 20 ml of 0.375% bupivacaine mixed with 10 ml contrast medium in the supine position (11 patients)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Interpleural injection of 20 ml of 0.375% bupivacaine mixed with 10 ml contrast medium in the lateral position (10 patients)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Interpleural injection of 20 ml of 0.375% bupivacaine mixed with 10 ml contrast medium
Number of subjects: 21
Study: 7386530

Group type: EXPERIMENTAL
Intervention: Intravenous glucose administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous saline solution administration
Number of subjects: 0
Study: 31468402

Group type: EXPERIMENTAL
Intervention: Dietary taurine supplementation (3 g of taurine)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (scorched rice water without taurine)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Dietary taurine supplementation
Number of subjects: 31